This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial

This study has been completed.
Information provided by (Responsible Party):
Ascensia Diabetes Care Identifier:
First received: April 1, 2011
Last updated: January 29, 2016
Last verified: January 2016
Subjects with diabetes and study staff used an investigational blood glucose monitoring system.

Condition Intervention
Diabetes Device: Contour Link Investigational Blood Glucose Monitoring System

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Trial Protocol for Contour Link System With Contour Sensor

Resource links provided by NLM:

Further study details as provided by Ascensia Diabetes Care:

Primary Outcome Measures:
  • Percent of Fingerstick Blood Glucose (BG) Results Within +/-20%(>=75 mg/dL) and Within +/- 15mg/dL (<75 mg/dL) of Laboratory Glucose Method [ Time Frame: 1 hour ]
    Subjects with diabetes and study staff tested subject fingerstick blood using an investigational blood glucose meter (BGM). BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 20% (for reference BG results >=75mg/dL) and within +/- 15mg/dL(for reference BG results <75mg/dL) of the reference method results.

Secondary Outcome Measures:
  • Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Evaluation) [ Time Frame: 1 hour ]
    Subjects read User Guide(UG)to learn to use the system and performed meter tasks. Study staff observed, then rated subjects' success (1 to 4) at performing tasks. Scale: 1.Performed tasks correctly without assistance. 2.Performed tasks correctly, but was directed to a specific part of the UG by the study staff as in a Customer Service call. 3.Performed tasks correctly, but required additional review/assistance similar to review of a specific function during a Customer Service call. 4.Subject incorrectly performed part of the testing regimen and was unaware of the error.

Enrollment: 78
Study Start Date: December 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intended Users of the System
Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
Device: Contour Link Investigational Blood Glucose Monitoring System
Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, 18 years of age and above
  • Diagnosed as having type 1 or type 2 diabetes
  • Currently self-testing blood glucose at home for at least three months
  • Able to speak, read, and understand English
  • Willing to complete all study procedures

Exclusion Criteria:

  • Gestational Diabetes
  • Hemophilia or any other bleeding disorder
  • Employee of competitive medical device company
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01328717

United States, Indiana
Bayer HealthCare LLC, Diabetes Care
Mishawaka, Indiana, United States, 46544
Sponsors and Collaborators
Ascensia Diabetes Care
Principal Investigator: David Simmons, MD Ascensia Diabetes Care
  More Information

Responsible Party: Ascensia Diabetes Care Identifier: NCT01328717     History of Changes
Other Study ID Numbers: R&D-2010-2011.09
Study First Received: April 1, 2011
Results First Received: April 27, 2012
Last Updated: January 29, 2016 processed this record on September 20, 2017